250 related articles for article (PubMed ID: 24848755)
21. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Tobe K; Suganami H; Kaku K
J Diabetes Investig; 2018 Jul; 9(4):862-869. PubMed ID: 29032638
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Tanizawa Y; Kaku K; Araki E; Tobe K; Terauchi Y; Utsunomiya K; Iwamoto Y; Watada H; Ohtsuka W; Watanabe D; Suganami H;
Expert Opin Pharmacother; 2014 Apr; 15(6):749-66. PubMed ID: 24512053
[TBL] [Abstract][Full Text] [Related]
23. Tofogliflozin: the road goes ever on.
Pafili K; Papanas N
Expert Opin Pharmacother; 2014 Jun; 15(9):1197-201. PubMed ID: 24787286
[TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
25. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Bloch MJ
J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
[No Abstract] [Full Text] [Related]
26. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).
Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Fujii S; Kakiuchi S; Fujiwara H; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2017 Nov; 8(6):766-775. PubMed ID: 28107773
[TBL] [Abstract][Full Text] [Related]
27. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
[TBL] [Abstract][Full Text] [Related]
29. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Skrtić M; Yang GK; Perkins BA; Soleymanlou N; Lytvyn Y; von Eynatten M; Woerle HJ; Johansen OE; Broedl UC; Hach T; Silverman M; Cherney DZ
Diabetologia; 2014 Dec; 57(12):2599-602. PubMed ID: 25280671
[No Abstract] [Full Text] [Related]
31. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
Katakami N; Mita T; Maeda N; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2022 Feb; 21(1):19. PubMed ID: 35123483
[TBL] [Abstract][Full Text] [Related]
32. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2020 Jul; 19(1):110. PubMed ID: 32646498
[TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
[TBL] [Abstract][Full Text] [Related]
34. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
Dalama B; Biagetti B; Mesa J
Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
[No Abstract] [Full Text] [Related]
35. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Garnock-Jones KP
Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
[TBL] [Abstract][Full Text] [Related]
36. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
37. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
[TBL] [Abstract][Full Text] [Related]
38. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
39. Empagliflozin (Jardiance) for diabetes.
Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
[No Abstract] [Full Text] [Related]
40. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Simonyi G
Orv Hetil; 2012 May; 153(18):695-701. PubMed ID: 22547464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]